1. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. published online May 2 (2020). DOI: 10.1093/cid/ciaa530.
2. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 323, 1061-9 (2020).
3. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. published online Mar 12 (2020).
4. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. published online Mar 20 (2020). DOI: 10.1016/j.ijantimicag.2020.105949.
5. Zheng YX, Chen J, Kong DC, et al. [Pathogenic characteristics of hospitalized severe acute respiratory infections in Shanghai, China, 2015-2017]. Zhonghua Liu Xing Bing Xue Za Zhi. 40, 911-916 (2019). (in Chinese)
6. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 323, 2052-9 (2020).
7. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. published online Feb 24 (2020).
8. Mason S, Devincenzo JP, Toovey S, Wu JZ, Whitley RJ. Comparison of antiviral resistance across acute and chronic viral infections. Antiviral Res. 158, 103-12 (2018).
9. Reardon S. Antibiotic treatment for COVID-19 complications could fuel resistant bacteria. 2020. https://www.sciencemag.org/news/2020/04/antibiotic-treatment-covid-19-complications-could-fuel-resistant-bacteria (accessed May 1, 2020)